Is perseris safe?

See the DrugPatentWatch profile for perseris

Is Perseris safe for most patients?

Perseris is an extended-release risperidone injection approved for schizophrenia in adults. Clinical trials showed the most common side effects were weight gain, sedation, and injection-site reactions, occurring at rates similar to other long-acting antipsychotics. Serious adverse events such as neuroleptic malignant syndrome and tardive dyskinesia remain possible but uncommon.

How does Perseris compare to oral risperidone on safety?

Because Perseris delivers the same active drug over one month, its side-effect profile closely matches daily oral risperidone. The main differences are injection-related pain or nodules and the inability to stop treatment quickly if problems arise. No new safety signals emerged in head-to-head studies.

What do long-term studies show about Perseris?

Open-label extensions up to one year reported stable safety data with no increase in metabolic or movement disorders beyond what is expected with risperidone. Discontinuation due to adverse events stayed below 10 percent.

Who should avoid Perseris?

Patients with known hypersensitivity to risperidone or any component of the formulation, or those with severe hepatic impairment, should not receive Perseris. Caution is advised in elderly patients with dementia-related psychosis because of an elevated risk of stroke and death.

Can Perseris be used safely with other medications?

Drug-interaction studies indicate Perseris shares the same CYP2D6 and CYP3A4 interactions as oral risperidone. Strong inhibitors or inducers of these enzymes may alter risperidone levels, so dose adjustments or alternative antipsychotics are often required.

When does the Perseris patent expire?

The primary U.S. composition-of-matter patent for Perseris expires in 2031, with possible pediatric exclusivity extending protection into 2032. After that date, generic long-acting risperidone formulations could enter the market, although formulation patents may delay full competition.

[1] https://www.drugpatentwatch.com/drug/perseris